Inhibitex Report issue

For profit Phase 2
Founded: Alpharetta GA United States (1994)
Status: Acquired by Bristol-Myers Squibb (2012)

Organization Overview

First Clinical Trial
2004
NCT00113191
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

tefibazumab (2 trials)

Drugs in Other Trials (1)

veronate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacteremia (Phase 2)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2